Analysis of dynamic traffic control and management strategies

Ph.DDOCTOR OF PHILOSOPH

Scenario-based electric bus operation: A case study of Putrajaya, Malaysia

Globally, transportation sector has emerged as one of the major sources of air pollution. Correspondingly, green mobility (with electric bus) is gaining increasing attention as an essential step to mitigate emission concern. As such, a proper electric bus network design and fleet planning is important especially for bus operator to acquire an adequate number of electric bus, right on time, in order to operate electric bus system viably. Thus, this paper aims to examine the possibility to operate electric bus as a replacement for the conventional bus operation (with natural gas buses for the study area in Putrajaya, Malaysia). In order to determine a proper-designed electric bus operating system in terms of electric bus route, service frequency and quantity, the proposed methodology is developed with the aid of a traffic modeling software to cater various scenarios. Based on the existing (conventional) traffic and transit system in Putrajaya, the developed electric bus operating model is calibrated accordingly by considering various operational concerns including battery capacity and charging facility. The resultant findings revealed that the developed electric bus operating system in Putrajaya outperforms the conventional bus operation, not only in generating a higher profit margin for the bus operator, but also satisfying the passengers in a better manner (by carrying more passengers per unit of bus with a lower energy consumption)

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo